Patents by Inventor Krystyna Tatarkiewicz

Krystyna Tatarkiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and apparatus for tritium-based true random number generator
    Patent number: 11048478
    Abstract: Methods are disclosed for manufacturing a true random number generator (TRNG), wherein the TRNG includes a cavity filled with tritium and an electronic sensor constructed to detect energy from the decay of the tritium. One method includes (a) forming the cavity by bonding an enclosing structure to the sensor or adjacent to the sensor such that a portion of the sensor forms an inner surface of the cavity, (b) injecting the tritium gas into the cavity via one or more ports in the enclosing structure, and (c) sealing the one or more ports. Another method includes (a) applying a drop of tritiated water or tritiated gel to a surface of the electronic sensor, and (b) applying epoxy over the drop of tritiated water or tritiated gel (prior to step (b), the surface of the electronic sensor may be cooled sufficiently to freeze the drop of tritiated water or tritiated gel).
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 29, 2021
    Assignee: RANDAEMON SP. Z O.O.
    Inventors: Jan Jakub Tatarkiewicz, Janusz Jerzy Borodzinski, Wieslaw Bohdan Kuzmicz, Krystyna Tatarkiewicz
  • Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
    Patent number: 8481490
    Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: July 9, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
  • GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS
    Publication number: 20120295850
    Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 22, 2012
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
  • Methods of using GLP-1 receptor agonists to treat pancreatitis
    Patent number: 8263554
    Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: September 11, 2012
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
  • GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS
    Publication number: 20110306549
    Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 15, 2011
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin